API
< Back to all clusters
[BUSINESS] · 2 sources

started · updated

Merck and BioNTech navigate shifting pharmaceutical landscapes

Merck & Co. is preparing for the upcoming patent expiration of its blockbuster oncology drug, Keytruda. According to GlobalData, Keytruda, which accounted for 58% of Merck’s total sales in 2025, faces market exclusivity expirations starting in the US in 2028, followed by Europe in 2031 and Japan in 2033. To mitigate a projected 57% decline in Keytruda revenues by 2032, Merck is focusing on its non-oncology portfolio, which is forecasted to double in footprint to reach $29.9 billion by 2032.

Meanwhile, BioNTech is undergoing a transformation into an oncology-focused company. While the company reported a net profit of €184.5 million in the third quarter, it recorded a net loss of €1.168 billion over the first nine months of the year due to high research and development expenses. BioNTech has raised its 2026 revenue guidance to a range of €1.7 billion to €1.9 billion, driven largely by milestone and licensing payments from collaborations, such as its partnership with Bristol Myers Squibb, rather than direct drug sales.

Entities

BioNTech · Bristol Myers Squibb · GlobalData · Keytruda · Merck & Co.